Cartilage Diseases Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight

April 15 06:32 2025
Cartilage Diseases Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight
Cartilage Diseases Treatment Market
Cartilage Diseases companies are Regeneron, TissueGene, Vericel Corporation, Genzyme Corporation, Eli Lilly and Company, Incyte Corporation, Astellas Pharma, Pfizer, Sanofi, among others. Promising Cartilage Diseases therapies are Olumiant (Baricitinib), Celebrex (Celecoxib), Motrin (Ibuprofen), Kevzara (Sarilumab), and others.

(Albany, USA) DelveInsight’s “Cartilage Diseases Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cartilage Diseases Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). The Cartilage Diseases market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

 

Request for a Free Sample Report @ Cartilage Disease Market Insight

 

Some facts of the Cartilage Diseases Market Report:

  • According to DelveInsight, Cartilage Diseases market is expected to grow at a decent CAGR by 2032.
  • Leading Cartilage Diseases companies working in the treatment market are Regeneron, TissueGene, Vericel Corporation, Genzyme Corporation, Eli Lilly and Company, Incyte Corporation, Astellas Pharma, Pfizer, Sanofi, among others.
  • Promising Cartilage Diseases therapies are Olumiant (Baricitinib), Celebrex (Celecoxib), Motrin (Ibuprofen), Kevzara (Sarilumab), and others.
  • In November 2024, Tetec AG has announced a Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of NOVOCART Inject for the Treatment of Cartilage Defects in the Knee in Pediatric Patients With Closed Epiphyses
  • In August 2024, Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size. MACI ArthroTM provides a less invasive technique compared to the current approach, allowing surgeons to evaluate and prepare the defect site as well as deliver the MACI implant through small incisions using custom-designed MACI Arthro instruments.
  • In August 2023, Biosolution Co., Ltd announced a Multi-Center, Open-Label, Phase 2 Trial to Evaluate the Efficacy and Safety of CartiLife® for Patients With Articular Cartilage Defects in the Knee

 

Cartilage Diseases Overview

Cartilage Disease, also known as cartilage disease, is related to multiple epiphyseal dysplasia and achondroplasia. Cartilage is a tough but flexible non-vascular type of supporting connective tissue that is found throughout the body. It covers the ends of bones at joints, and it also gives shape and support to body parts such as the ears, nose, and windpipe. Healthy cartilage helps joint articulation by allowing bones to glide smoothly over each other. It protects bones by preventing them from rubbing against each other. Cartilage disease can have major symptoms such as back pain, sciatica, and muscle cramp. Sports injuries, genetic factors, and different types of arthritis are some of the key causes of cartilage problems that may result in tears and injuries.

 

Learn more about Cartilage Disease, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Cartilage Disease Treatment Market

 

Cartilage Diseases Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cartilage Diseases market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Cartilage Diseases market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

The Cartilage Diseases market is primarily driven by the rising prevalence of osteoarthritis and other degenerative joint disorders, an aging global population, and the growing demand for minimally invasive treatment options. Advances in regenerative medicine, including stem cell and tissue engineering therapies, along with increased investments in research and development, are further propelling market growth. However, the market faces several barriers, such as the high cost of advanced therapies, limited availability of effective treatment options for late-stage cartilage damage, and stringent regulatory approval processes. Additionally, the lack of awareness and access to specialized treatment in developing regions poses a significant challenge to market expansion.

 

Explore more about Cartilage Disease Epidemiology @ Cartilage Disease Prevalence

 

Cartilage Diseases Epidemiology

The epidemiology section covers detailed insights into the historical and current Cartilage Diseases patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Cartilage Diseases Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cartilage Diseases market or expected to get launched in the market during the study period. The analysis covers Cartilage Diseases market uptake by drugs, patient uptake by therapies, and sales of each drug. Olumiant (Baricitinib): Eli Lilly and Company/Incyte Corporation

  • Celebrex (Celecoxib): Astellas Pharma/Pfizer
  • Motrin (Ibuprofen): Pfizer
  • Kevzara (Sarilumab): Regeneron/Sanofi

 

Request for a sample report to understand more about the Cartilage Disease pipeline development activities @ Cartilage Disease Companies and Medication

 

Cartilage Diseases Therapeutics Assessment

Major key companies are working proactively in the Cartilage Diseases Therapeutics market to develop novel therapies which will drive the Cartilage Diseases treatment markets in the upcoming years are Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), TissueGene Inc. (KOSDAQ: 950160), Vericel Corporation (NASDAQ: VCEL), Genzyme Corporation (acquired by Sanofi), Eli Lilly and Company (NYSE: LLY), Incyte Corporation (NASDAQ: INCY), Astellas Pharma Inc. (TYO: 4503), Pfizer Inc. (NYSE: PFE), Sanofi (EPA: SAN), among others.

 

Learn more about the emerging therapies & key companies @ Cartilage Disease Clinical Trials and Drug Approvals

 

Cartilage Diseases Report Key Insights

1. Cartilage Diseases Patient Population

2. Cartilage Diseases Market Size and Trends3. Key Cross Competition in the Cartilage Diseases Market

4. Cartilage Diseases Market Dynamics (Key Drivers and Barriers)

5. Cartilage Diseases Market Opportunities

6. Cartilage Diseases Therapeutic Approaches

7. Cartilage Diseases Pipeline Analysis

8. Cartilage Diseases Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Cartilage Diseases Market

 

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Cartilage Diseases Competitive Intelligence Analysis

4. Cartilage Diseases Market Overview at a Glance

5. Cartilage Diseases Disease Background and Overview

6. Cartilage Diseases Patient Journey

7. Cartilage Diseases Epidemiology and Patient Population

8. Cartilage Diseases Treatment Algorithm, Current Treatment, and Medical Practices

9. Cartilage Diseases Unmet Needs

10. Key Endpoints of Cartilage Diseases Treatment

11. Cartilage Diseases Marketed Products

12. Cartilage Diseases Emerging Therapies

13. Cartilage Diseases Seven Major Market Analysis

14. Attribute Analysis

15. Cartilage Diseases Market Outlook (7 major markets)

16. Cartilage Diseases Access and Reimbursement Overview

17. KOL Views on the Cartilage Diseases Market.

18. Cartilage Diseases Market Drivers

19. Cartilage Diseases Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services